Organon & FCO/Dettes

Que fait Organon & ? Organon & Co., trading under the ticker symbol OGN and identified by ISIN US68622V1061, stands as a prominent entity within the global healthcare sector, specifically categorized under the pharmaceuticals industry. Headquartered in Jersey City, New Jersey, the United States, the company operates as a science-based global pharmaceutical organization dedicated to developing and delivering innovative health solutions. Since its initial public offering on May 14, 2021, Organon has established itself as a significant player in the market, employing approximately 10,000 full-time staff members who contribute to its extensive research, development, and commercialization efforts. The firm’s strategic focus is centered on a robust portfolio of prescription therapies and medical devices, primarily targeting three key therapeutic areas: women’s health, biosimilars, and established brands. In the realm of women’s health, Organon offers a diverse array of contraception and fertility products. Notable brands within this segment include Nexplanon, Implanon NXT, and NuvaRing, which address various contraceptive needs, alongside fertility treatments such as Follistim AQ and Elonva. These products are designed to provide comprehensive care for patients seeking reproductive health solutions. The company’s biosimilars portfolio is equally substantial, spanning critical treatments in immunology and oncology. This segment reflects Organon’s commitment to providing high-quality, accessible alternatives to biologic medicines, thereby supporting broader patient access to essential therapies. Additionally, the established brands division encompasses a wide range of products in cardiovascular, respiratory, dermatology, and non-opioid pain management. These legacy brands continue to serve a global patient base, ensuring continuity of care for chronic and acute conditions. Organon distributes its products through a multifaceted channel strategy, engaging with drug wholesalers and retailers, hospitals, government agencies, and managed healthcare providers. This includes partnerships with health maintenance organizations and pharmacy benefit managers, ensuring that its innovative solutions reach healthcare institutions and individual patients efficiently. By leveraging its scientific expertise and extensive distribution network, Organon & Co. aims to improve health outcomes worldwide, maintaining its position as a vital contributor to the global pharmaceutical landscape. Organon & est l'une des entreprises les plus populaires sur Eulerpool.